Full Press Release Details
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
New York, NY May 14,
2024: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its
T-win platform, today reported financial results for the first quarter ended March 31, 2024.
This will be a transformative year for IO Biotech as we approach the interim analysis of our pivotal Phase 3 study in first-line
advanced melanoma, which, if supportive, could allow for a submission of a Biologics License Application (BLA) to the United States (US) Food and Drug Administration (FDA) this year, said Mai-Britt
Zocca, Ph.D., President and CEO of IO Biotech. Last year, we expanded our Phase 3 study to potentially bring in the time to reach the primary endpoint of progression free survival and we concluded enrollment in the fourth quarter of 2023 with
407 patients. As we prepare for the interim analysis, we now have greater visibility to estimate the timing of reaching 226 events needed for the PFS analysis, which we now project will occur in the first half of 2025.
Dr. Zocca continued, With continued execution of our Phase 3 study and its planned interim analysis as our main priorities this
year, we also continue both of our Phase 2 basket studies: completing enrollment in our IOB-022 study; and rapidly enrolling and expanding our newest basket study,
IOB-032, in the neo-adjuvant/adjuvant settings of melanoma and squamous cell carcinoma of the head and neck (SCCHN). Finally, as we prepare for potential
commercialization and partnering, I am very pleased with the strength of expertise we have added to our leadership team with the additions of Marjan Shamsaei as Senior Vice President, Commercial and Portfolio Lead, and Fai al Miyara as Chief
Business Officer. I founded IO Biotech 10 years ago and couldn t be more proud of all that we have accomplished, and, with such a strong team in place, confident in what lies ahead.
Recent Business Highlights
First Quarter 2024 Financial Results
IO102-IO103 is an investigational off-the-shelf therapeutic
cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO)
positive and programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial
(IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with advanced melanoma, a Phase 2 basket
trial (IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in combination with pembrolizumab as first line treatment in patients with solid tumors, and a Phase 2
basket trial (IOB-032/PN-E40; NCT05280314) investigating IO102-IO103 in combination with pembrolizumab as neo-adjuvant/adjuvant
treatment of patients with solid tumors.
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck and
Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
KEYTRUDA is a registered trademark
of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About the IOB-013/KN-D18 Pivotal Phase 3 Clinical Trial
IOB-013/KN-D18 (Clinical Trials.gov: NCT05155254) is an open label, randomized Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously
untreated, unresectable or metastatic (advanced) melanoma, being conducted in collaboration with Merck. Patients have been enrolled from centers across the United States, Europe, Australia, Turkey, Israel and South Africa. The primary endpoint of
the study is progression free survival. Biomarker analyses will also be conducted. IO Biotech is sponsoring the Phase 3 trial and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About the IOB-013/KN-D18 Clinical Trial Endpoints
The primary endpoint of the IOB-013/KN-D18 trial is progression
free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the first half of 2025. Additionally, there is a planned per-protocol interim analysis of overall response rate when the first 225 randomized patients reach one year of treatment in mid-2024. The outcome of this analysis is expected
in the third quarter of 2024. There is a high statistical bar for the Phase 3 interim analysis (p 0.005), which was set to preserve most of the alpha for the primary endpoint of PFS. Regardless of the outcome of the interim analysis, the trial
is designed to continue to the primary PFS endpoint.
IOB-022/KN-D38 Phase 2 Solid Tumor Basket Trial
IOB-022/KN-D38 (NCT05077709) is a non-comparative, open label trial to investigate the safety and efficacy of IO102-IO103 in
combination with pembrolizumab in first-line advanced cancers in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). IO Biotech is sponsoring the Phase 2 trial and
Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.
About IOB-032/PN-E40 Phase 2 Solid Tumor Basket Trial
IOB-032/PN-E40 (NCT05280314) is a Phase 2 basket trial investigating the IO102-IO103 therapeutic cancer vaccine in combination with pembrolizumab as
neo-adjuvant/adjuvant treatment of patients with solid tumors. The study will enroll approximately 15 patients with melanoma and 15 patients with SCCHN in cohort A and cohort B respectively as single arm
cohorts receiving combination of IO102-IO103 with pembrolizumab, whereas in cohort C 30 melanoma patients will be randomized 1:1 to neo-adjuvant treatment with either the combination of IO102-IO103 with
pembrolizumab or pembrolizumab alone. In the neo-adjuvant period, for all cohorts, treatment is every 3 weeks (Q3W) for 3 cycles
(melanoma) or 2-3 cycles (SCCHN). Patients entering the study will be scheduled for surgery and begin neoadjuvant treatment
4-9 weeks prior. Surgery will be followed by adjuvant treatment with the same regimen for 15 cycles. Cohort C patients with poor pathological response to pembrolizumab alone in the neo-adjuvant phase (>10% residual viable tumor) may cross over to combination treatment post-surgery. The primary endpoint is major pathological response at surgery ( 10% residual viable tumor; central
assessment). IO Biotech is sponsoring the Phase 2 trial and Merck is supplying pembrolizumab.
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to
target the immunosuppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, IO102-IO103, in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase
1/2 first line metastatic melanoma data, IO102-IO103, in combination with pembrolizumab, has been granted a breakthrough therapy designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered
in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing of the interim and primary analyses of the company s Phase 3 trial, current or future clinical trials, their
progress, enrollment or results, or the company s financial position or cash runway, are based on IO Biotech s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations
or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These
forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information,
future developments or otherwise.
Maryann Cimino, Director of Investor Relations
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Operating expenses | ||||||||
| Research and development | $ | 14,311 | $ | 11,900 | ||||
| General and administrative | 5,886 | 6,024 | ||||||
| Total operating expenses | 20,197 | 17,924 | ||||||
| Loss from operations | (20,197 | ) | (17,924 | ) | ||||
| Other income (expense) | ||||||||
| Currency exchange (loss) gain, net | (462 | ) | 258 | |||||
| Interest income | 1,617 | 1,028 | ||||||
| Total other income (expense) | 1,155 | 1,286 | ||||||
| Loss before income tax expense | (19,042 | ) | (16,638 | ) | ||||
| Income tax expense | 415 | 406 | ||||||
| Net loss | (19,457 | ) | (17,044 | ) | ||||
| Net loss attributable to common shareholders | (19,457 | ) | (17,044 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.30 | ) | $ | (0.59 | ) | ||
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 65,880,914 | 28,815,267 | ||||||
| Other comprehensive loss | ||||||||
| Net loss | $ | (19,457 | ) | $ | (17,044 | ) | ||
| Foreign currency translation | 194 | 517 | ||||||
| Total comprehensive loss | $ | (19,263 | ) | $ | (16,527 | ) |
Consolidated Balance Sheets
(Unaudited in thousands, except share and per share amounts)
| March 31, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 117,982 | $ | 143,193 | ||||
| Prepaid expenses and other current assets | 6,146 | 4,062 | ||||||
| Total current assets | 124,128 | 147,255 | ||||||
| Restricted cash | 268 | 268 | ||||||
| Property and equipment, net | 788 | 847 | ||||||
| Right of use lease asset | 2,092 | 2,259 | ||||||
| Other non-current assets | 883 | 89 | ||||||
| Total non-current assets | 4,031 | 3,463 | ||||||
| Total assets | $ | 128,159 | $ | 150,718 | ||||
| Liabilities and stockholders equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 3,840 | $ | 3,878 | ||||
| Lease liability - current | 666 | 655 | ||||||
| Accrued expenses and other current liabilities | 6,537 | 11,184 | ||||||
| Total current liabilities | 11,043 | 15,717 | ||||||
| Lease liability - non-current | 1,650 | 1,839 | ||||||
| Total non-current liabilities | 1,650 | 1,839 | ||||||
| Total liabilities | 12,693 | 17,556 | ||||||
| Commitments and contingencies (Note 9) | ||||||||
| Stockholders equity | ||||||||
| Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||||||||
| Common stock, par value of $0.001 per share; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 65,880,914 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 66 | 66 | ||||||
| Additional paid-in capital | 408,154 | 406,587 | ||||||
| Accumulated deficit | (283,279 | ) | (263,822 | ) | ||||
| Accumulated other comprehensive loss | (9,475 | ) | (9,669 | ) | ||||
| Total stockholders equity | 115,466 | 133,162 | ||||||
| Total liabilities and stockholders equity | $ | 128,159 | $ | 150,718 |